Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Revenue: 2009-2024

Historic Revenue for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $37.9 million.

  • Cumberland Pharmaceuticals' Revenue fell 8.73% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.3 million, marking a year-over-year increase of 12.21%. This contributed to the annual value of $37.9 million for FY2024, which is 4.26% down from last year.
  • As of FY2024, Cumberland Pharmaceuticals' Revenue stood at $37.9 million, which was down 4.26% from $39.6 million recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Revenue ranged from a high of $42.0 million in FY2022 and a low of $36.0 million during FY2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Revenue averaged around $39.8 million, with its median value being $39.6 million (2023).
  • Its Revenue has fluctuated over the past 5 years, first grew by 16.75% in 2022, then fell by 5.85% in 2023.
  • MRY analysis of 5 years shows Cumberland Pharmaceuticals' Revenue stood at $37.4 million in 2020, then dropped by 3.89% to $36.0 million in 2021, then increased by 16.75% to $42.0 million in 2022, then fell by 5.85% to $39.6 million in 2023, then fell by 4.26% to $37.9 million in 2024.
  • Its last three reported values are $37.9 million in FY2024, $39.6 million for FY2023, and $42.0 million during FY2022.